Maxcyte annual free cash flow
2019
2020
2021
2022
2023
2024
2025
Maxcyte Free Cash Flow (FCF) History (MXCT)
Maxcyte reported −$36.2M in free cash flow for fiscal 2025, a decrease of $6.9M from the previous fiscal year, with a free cash flow margin of −172.63%.
View full Maxcyte company overviewMaxcyte free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$36.2M | −$6.9M | — | −172.63% |
| 2024 | 2024-12-31 | −$29.3M | −$3.9M | — | −131.72% |
| 2023 | 2023-12-31 | −$25.4M | $7.9M | — | −130.20% |
| 2022 | 2022-12-31 | −$33.3M | −$18.7M | — | −115.70% |
| 2021 | 2021-12-31 | −$14.5M | −$3.7M | — | −67.28% |
| 2020 | 2020-12-31 | −$10.9M | −$780,400 | — | −70.25% |
| 2019 | 2019-12-31 | −$10.1M | — | — | −75.99% |
Maxcyte quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$4.7M | $5.7M | — | −95.68% |
| Q1 2026 | 2026-03-31 | −$8.2M | $6.8M | — | −183.09% |
| Q4 2025 | 2025-12-31 | −$2.9M | $5.0M | — | −61.00% |
| Q3 2025 | 2025-09-30 | −$7.8M | −$3.0M | — | −168.54% |
| Q2 2025 | 2025-06-30 | −$10.4M | −$5.3M | — | −179.19% |
| Q1 2025 | 2025-03-31 | −$15.1M | −$3.7M | — | −262.30% |
| Q4 2024 | 2024-12-31 | −$8.0M | −$8.0M | — | −131.62% |
| Q3 2024 | 2024-09-30 | −$4.8M | $4.2M | — | −85.48% |
| Q2 2024 | 2024-06-30 | −$5.1M | $5.5M | — | −103.28% |
| Q1 2024 | 2024-03-31 | −$11.4M | −$5.5M | — | −203.58% |
| Q4 2023 | 2023-12-31 | $66,000 | $8.3M | — | +1.39% |
| Q3 2023 | 2023-09-30 | −$9.0M | $440,800 | — | −215.54% |
| Q2 2023 | 2023-06-30 | −$10.6M | −$4.7M | — | −188.76% |
| Q1 2023 | 2023-03-31 | −$5.9M | $3.8M | — | −118.49% |
| Q4 2022 | 2022-12-31 | −$8.3M | −$6.2M | — | −106.76% |
| Q3 2022 | 2022-09-30 | −$9.4M | −$7.3M | — | −131.41% |
| Q2 2022 | 2022-06-30 | −$5.9M | −$537,300 | — | −84.31% |
| Q1 2022 | 2022-03-31 | −$9.7M | −$4.7M | — | −141.36% |
| Q4 2021 | 2021-12-31 | −$2.1M | −$588,700 | — | −27.75% |
| Q3 2021 | 2021-09-30 | −$2.1M | — | — | −38.00% |
| Q2 2021 | 2021-06-30 | −$5.3M | — | — | −126.81% |
| Q1 2021 | 2021-03-31 | −$5.0M | — | — | −116.79% |
| Q3 2020 | 2020-09-30 | −$1.5M | — | — | −31.99% |
Maxcyte free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$10.9M to −$36.2M, a net decrease of $25.3M. Maxcyte's latest reported quarter, Q2 2026, generated −$4.7M in free cash flow, an increase of $5.7M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Maxcyte filings at SEC.gov ↗